The findings counsel that GLP-1 receptor agonists might lower a diabetic affected person’s danger of growing glaucoma by half.
The findings are supported by a Penn Medicine examine from 2020, which discovered that GLP-1R agonists lowered neuroinflammation and prevented retinal ganglion cell dying in mice.
This class of medication has additionally proven equally protecting results in opposition to Alzheimer’s and Parkinson’s ailments in animal fashions, and scientific trials are underway to check the medicines in opposition to neurodegenerative ailments in people.
Glaucoma impacts 3 million Americans and is the second main reason for blindness worldwide. People with diabetes are twice as prone to develop the attention situation.
“It was very encouraging to see that a popular diabetes medication could significantly reduce the risk of developing glaucoma, and our study suggests that these medications warrant further study in this patient population,” says Qi N. Cui, MD, PhD, with Brian VanderBeek, MD, MPH, each assistant professors of Ophthalmology at Penn.
Source: Eurekalert
